901
Views
33
CrossRef citations to date
0
Altmetric
Research Article

Pharmacogenetic Screening of the Gene Deletion and Duplications of CYP2D6

, , , &
Pages 45-60 | Published online: 09 Oct 2008

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Articles from other publishers (32)

Debbie M. Figueroa, Ender Karaca, Blake Atwood & Michele Erickson-Johnson. 2022. Clinical Decision Support for Pharmacogenomic Precision Medicine. Clinical Decision Support for Pharmacogenomic Precision Medicine 53 84 .
Lilia Romdhane, Nessrine Mezzi, Hamza Dallali, Olfa Messaoud, Jingxuan Shan, Khalid A. Fakhro, Rym Kefi, Lotfi Chouchane & Sonia Abdelhak. (2021) A map of copy number variations in the Tunisian population: a valuable tool for medical genomics in North Africa. npj Genomic Medicine 6:1.
Crossref
Madoka Kisoi, Miho Imai, Miwako Yamamura, Yui Sakaguchi, Shigenori Murata, Atsushi Ichikawa & Kenji Kinoshita. (2020) Unique Genotyping Protocol of CYP2D6 Allele Frequency Using Real Time Quantitative PCR from Japanese Healthy Women. Biological and Pharmaceutical Bulletin 43:5, pages 904-907.
Crossref
Yaqiong Jin, Geng Chen, Wenming Xiao, Huixiao Hong, Joshua Xu, Yongli Guo, Wenzhong Xiao, Tieliu Shi, Leming Shi, Weida Tong & Baitang Ning. (2019) Sequencing XMET genes to promote genotype-guided risk assessment and precision medicine. Science China Life Sciences 62:7, pages 895-904.
Crossref
Kanokpich Puaprasert, Cindy Chu, Naowarat Saralamba, Nicholas P. J. Day, Francois Nosten, Nicholas J. White, Arjen M. Dondorp & Mallika Imwong. (2018) Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study. Malaria Journal 17:1.
Crossref
Kirsten M. Pondman, Ron H.N. van Schaik & Jan van der Weide. (2018) Accurate determination of the CYP2D6 (*1/*4)xN genotype by quantitative PCR. Drug Metabolism and Personalized Therapy 33:1, pages 33-39.
Crossref
T. Harel & J.R. Lupski. (2018) Genomic disorders 20 years on-mechanisms for clinical manifestations. Clinical Genetics 93:3, pages 439-449.
Crossref
Edward Ki Yun Leung, Emanuele Agolini, Xun Pei, Roberta Melis, Gwendolyn A McMillin, Paula N Friedman, Patrick Peterson, Keith Danahey, Peter H O'Donnell & Kiang-Teck J Yeo. (2017) Validation of an Extensive CYP2D6 Assay Panel Based on Invader and TaqMan Copy Number Assays . The Journal of Applied Laboratory Medicine 1:5, pages 471-482.
Crossref
Keqin Gregg, Wenjing Guo, Robert Rhodes, Ashrita Simhadri, Archana Subramanya, Paul Samilpa, Lyndsey Langley, Kyle Ames & Matt McCarty. (2016) Are you sure the patient is a CYP2D6 ultra-rapid metabolizer?. Pharmacogenomics 17:16, pages 1749-1763.
Crossref
C. D. Bostick, K. M. Hickey, L. A. Wollenberg, D. R. Flora, T. S. Tracy & P. M. Gannett. (2016) Immobilized Cytochrome P450 for Monitoring of P450-P450 Interactions and Metabolism. Drug Metabolism and Disposition 44:5, pages 741-749.
Crossref
Delphine Allorge. (2016) La pharmaco-toxicogénétique et ses applications médicales. Revue Francophone des Laboratoires 2016:479, pages 51-58.
Crossref
Daniel L. Hertz, Anna C. Snavely, Howard L. McLeod, Christine M. Walko, Joseph G. Ibrahim, Steven Anderson, Karen E. Weck, Gustav Magrinat, Oludamilola Olajide, Susan Moore, Rachel Raab, Daniel R. Carrizosa, Steven Corso, Garry Schwartz, Jeffrey M. Peppercorn, James P. Evans, David R. Jones, Zeruesenay Desta, David A. Flockhart, Lisa A. Carey & William J. IrvinJrJr. (2015) In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles . British Journal of Clinical Pharmacology 80:5, pages 1122-1130.
Crossref
Nelson Varela, Luis A. Quiñones, Jana Stojanova, Joselyn Garay, Dante Cáceres, Silvia Cespedes, Jaime Sasso & Carla Miranda. (2015) Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses. Pharmacological Research 101, pages 124-129.
Crossref
Taimour Langaee, Issam Hamadeh, Arlene B. Chapman, John G. Gums & Julie A. Johnson. (2015) A Novel Simple Method for Determining CYP2D6 Gene Copy Number and Identifying Allele(s) with Duplication/Multiplication. PLOS ONE 10:1, pages e0113808.
Crossref
Friederike Flachsbart, Michael Möller, Carolin Däumer, Liljana Gentschew, Rabea Kleindorp, Michael Krawczak, Amke Caliebe, Stefan Schreiber & Almut Nebel. (2012) Genetic investigation of FOXO3A requires special attention due to sequence homology with FOXO3B. European Journal of Human Genetics 21:2, pages 240-242.
Crossref
Stuart A ScottManishkumar PatelSuparna MartisSteven A Lubitz, Sarina van der Zee, Chang Yoo, Lisa EdelmannJonathan L Halperin & Robert J Desnick. (2012) Copy number variation and warfarin dosing: evaluation of CYP2C9 , VKORC1 , CYP4F2 , GGCX and CALU . Pharmacogenomics 13:3, pages 297-307.
Crossref
Alexander V. LyubimovAnahita Bhathena & David A. Katz. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions 1 27 .
Alexander V. LyubimovJoshua G. DeKeyser & Magang Shou. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions 1 38 .
D. Allorge,G. Tournel,A. Garat. 2012. Traité De Toxicologie Médico-judiciaire. Traité De Toxicologie Médico-judiciaire 73 98 .
Britt I DrögemöllerGalen EB WrightDana JH Niehaus, Robin A Emsley & Louise Warnich. (2011) Whole-genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications. Pharmacogenomics 12:12, pages 1717-1728.
Crossref
Deepika Singh, Akriti Kashyap, Ram Vinay Pandey & Kulvinder Singh Saini. (2011) Novel advances in cytochrome P450 research. Drug Discovery Today 16:17-18, pages 793-799.
Crossref
Delphine Allorge & Gilles Tournel. 2011. Forensic Science Advances and Their Application in the Judiciary System. Forensic Science Advances and Their Application in the Judiciary System 133 153 .
Anuradha Ramamoorthy & Todd C Skaar. (2011) Gene copy number variations: it is important to determine which allele is affected. Pharmacogenomics 12:3, pages 299-301.
Crossref
Anuradha Ramamoorthy, David A. Flockhart, Naoya Hosono, Michiaki Kubo, Yusuke Nakamura & Todd C. Skaar. (2010) Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays. Pharmacogenetics and Genomics 20:7, pages 451-454.
Crossref
Emily A. Vucic, Kelsie L. Thu, Ariane C. Williams, Wan L. Lam & Bradley P. Coe. 2010. Genetic Variation. Genetic Variation 103 117 .
Naoya Hosono, Mamoru Kato, Kazuma Kiyotani, Taisei Mushiroda, Sadaaki Takata, Hiroko Sato, Hanae Amitani, Yumiko Tsuchiya, Keiko Yamazaki, Tatsuhiko Tsunoda, Hitoshi Zembutsu, Yusuke Nakamura & Michiaki Kubo. (2009) CYP2D6 Genotyping for Functional-Gene Dosage Analysis by Allele Copy Number Detection. Clinical Chemistry 55:8, pages 1546-1554.
Crossref
Murali Subramanian, Michael Low, Charles W. Locuson & Timothy S. Tracy. (2009) CYP2D6-CYP2C9 Protein-Protein Interactions and Isoform-Selective Effects on Substrate Binding and Catalysis. Drug Metabolism and Disposition 37:8, pages 1682-1689.
Crossref
Luis J. Leandro-García, Susanna Leskelä, Cristina Montero-Conde, Iñigo Landa, Elena López-Jimenez, Rocío Letón, Angela Seeringer, Julia Kirchheiner, Alberto Cascón, Mercedes Robledo & Cristina Rodríguez-Antona. (2009) Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis. Analytical Biochemistry 389:1, pages 74-76.
Crossref
Wolfgang W. Huber & Michael Grusch. 2009. Chemoprevention of Cancer and DNA Damage by Dietary Factors. Chemoprevention of Cancer and DNA Damage by Dietary Factors 245 261 .
Ai-Ming Yu, Jun Qu, Melanie A. Felmlee, Jin Cao & Xi-Ling Jiang. (2009) Quantitation of Human Cytochrome P450 2D6 Protein with Immunoblot and Mass Spectrometry Analysis. Drug Metabolism and Disposition 37:1, pages 170-177.
Crossref
Jian Qin, Robert C. Jones & Ramesh Ramakrishnan. (2008) Studying copy number variations using a nanofluidic platform. Nucleic Acids Research 36:18, pages e116-e116.
Crossref
Stefan Vegter, Cornelis Boersma, Mark Rozenbaum, Bob Wilffert, GerJan Navis & Maarten J Postma. (2008) Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes. PharmacoEconomics 26:7, pages 569-587.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.